Novel therapeutics could offer clinicians an additional tool in developing their patient treatment plans, particularly for those with no response or resistance to existing therapies.
Famed microbiome researcher Dr Martin J. Blaser shares what he sees as the most promising applications, and the rigorous clinical trials needed to realize them.
Microbial diversity affects whether a tumor grows, leads to inflammation, develops immune escape mechanisms, or develops therapeutic resistance, said an internal medicine specialist.
The American Academy of Pediatrics endorsed fecal transplants to eliminate a particular infection in children and called for more research about other uses.